 Merus N.V. MRUS, a clinical-stage bispecific antibody company developing Biclonics, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of 14.50 per share, before underwriting discounts and commissions. Merus also granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately 68.9 million, excluding any exercise of the underwriters option to purchase additional common shares. 